Evidence map›Paper›PMID 29446043›Full record

ArticleInternational journal of clinical oncology2018

Long-term outcomes of postoperative taxane/platinum chemotherapy for early stage cervical cancer: a retrospective study.

Mika Okazawa-Sakai, Takanori Yokoyama, Etsuko Fujimoto, Shinichi Okame, Yuko Shiroyama, Takashi Yokoyama, Kazuhiro Takehara

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mika Okazawa-SakaiDepartment of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center, Ko-160 Minami-umemoto, Matsuyama, Ehime, 7910280, Japan. misakai@shikoku-cc.go.jp.ORCID http://orcid.org/0000-0002-6439-856X
Takanori YokoyamaDepartment of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center, Ko-160 Minami-umemoto, Matsuyama, Ehime, 7910280, Japan.
Etsuko FujimotoDepartment of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center, Ko-160 Minami-umemoto, Matsuyama, Ehime, 7910280, Japan.
Shinichi OkameDepartment of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center, Ko-160 Minami-umemoto, Matsuyama, Ehime, 7910280, Japan.
Yuko ShiroyamaDepartment of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center, Ko-160 Minami-umemoto, Matsuyama, Ehime, 7910280, Japan.
Takashi YokoyamaDepartment of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center, Ko-160 Minami-umemoto, Matsuyama, Ehime, 7910280, Japan.
Kazuhiro TakeharaDepartment of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center, Ko-160 Minami-umemoto, Matsuyama, Ehime, 7910280, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTaxane/platinum (TP)-based combination chemotherapy is standard for the treatment of metastatic or recurrent cervical cancer. The aim of this study was to investigate the efficacy of postoperative TP therapy in early stage cervical cancer.

methodsA retrospective review of patients with FIGO IB-IIB stage cervical cancer who were treated with radical hysterectomy and displayed surgical-pathological risk factors was performed. 122 patients were identified between 2003 and 2012. Survival was analyzed by Kaplan-Meier method and compared by the log-rank test. The Cox proportional hazards model was used to investigate predictors of survival.

resultsThe median follow-up period was 82.4 months. The postoperative adjuvant therapy was TP in 82 (67.2%) patients, other chemotherapies in 10 (8.2%), radiotherapy (RT) in 25 (20.5%), and no further therapy (NFT) in 5 (4.1%). Survival was analyzed using 4 subgroups according to the postoperative adjuvant therapy. The estimated 5-year overall survival was 95.1% in the TP group, 90.0% in the other chemotherapy group, 78.9% in the RT group, and 100% in the NFT group. No significant difference of survival was observed in the subgroups. However, when analyzing only patients who displayed high-risk factors, non-TP adjuvant therapy (including RT and other chemotherapies) was independently associated with shorter survival on multivariate analysis. In the TP group, multivariate analysis revealed that a positive surgical margin was a significant predictor of shorter survival.

conclusionsPostoperative TP is effective in patients with surgically treated early stage cervical cancer. In these populations, a positive surgical margin could be associated with poor prognosis.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBridged-Ring CompoundsCarcinoma, Squamous CellCombined Modality TherapyFemaleHumansHysterectomyLymphatic MetastasisMiddle AgedNeoplasm InvasivenessNeoplasm Recurrence, LocalPlatinumPostoperative CarePrognosisBridged-Ring CompoundsPlatinumtaxaneTaxoidsAdjuvant therapyCervical cancerRadical hysterectomyRecurrenceSurvivalTaxane/platinum

Identifiers

PMID29446043

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.